Onconetix, Inc. Addresses Nasdaq Late Filing Notice
Onconetix, Inc. (NASDAQ: ONCO) recently informed stakeholders about an important communication received from The Nasdaq Capital Market. The notification detailed a violation concerning the timely filing of its Quarterly Report on Form 10-Q for the period ending September 30, 2024.
Understanding the Nasdaq Notification
The letter from Nasdaq, dated December 6, 2024, raised concerns over the company's overdue submission of its financial report. This situation occurs under Nasdaq's continued listing requirements, highlighting the critical nature of timely filings for maintaining market activity.
Actions Taken by Onconetix, Inc.
In response to this notification, Onconetix acted swiftly and managed to complete and submit the Form 10-Q to the Securities and Exchange Commission by December 10, 2024. This action reflects the company's commitment to transparency and regulatory compliance.
About Onconetix, Inc. and Its Focus Areas
Onconetix operates as a relatively young biotechnology firm that emphasizes research and innovative solutions pertaining specifically to men's health and oncology. Following a strategic acquisition of Proteomedix, the company is making strides with Proclarix®, an in vitro diagnostic test tailored for prostate cancer. This product is noteworthy for being approved for sale within the European Union under the new In Vitro Diagnostic Regulation.
Innovative Medical Solutions
In addition to Proclarix®, Onconetix is proud to introduce ENTADFI, an FDA-approved medication designed to treat benign prostatic hyperplasia (BPH). This medication conveniently combines finasteride and tadalafil into a once-daily pill, enhancing patient accessibility to important therapeutic options.
Commitment to Men's Health
The focus of Onconetix on men’s health serves as a catalyst for broader discussions around prostate health and the importance of timely diagnostics. This approach includes tackling prevalent issues within this demographic, leading to improved health outcomes.
Communication and Contact Details
For investors and other stakeholders seeking further information about Onconetix, the company emphasizes open lines of communication. Onconetix, Inc. can be reached at:
201 E. Fifth Street, Suite 1900
Cincinnati, OH 45202
Phone: (513) 620-4101
Contacting Investor Relations
For inquiries related to investments, the Investor Relations team at Onconetix is available at:
Email: investors@onconetix.com
Frequently Asked Questions
What is the significance of the Nasdaq notice to Onconetix?
The Nasdaq notice highlights the need for Onconetix to adhere to financial filing deadlines crucial for maintaining its listing status.
How did Onconetix respond to the late filing?
Onconetix promptly filed the overdue Form 10-Q with the Securities and Exchange Commission to address the issue raised by Nasdaq.
What does Onconetix focus on in the biotechnology field?
The company primarily concentrates on developing innovative solutions for men's health and oncology, including diagnostic and therapeutic products.
What are the company's flagship products?
Onconetix's notable products include Proclarix®, a prostate cancer diagnostic test, and ENTADFI, a treatment for benign prostatic hyperplasia.
How can stakeholders get in touch with Onconetix?
Stakeholders can contact Onconetix through their corporate office or directly via the investor relations email for any inquiries.